Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report.

Chiu CT, Hu YH, Chang CH

SAGE open medical case reports1 Jul 2026

PMID42395841PMCIDPMC13323645DOI10.1177/2050313x261463142PepBankPUB-42395841

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanCase report or seriesSafety outcome
In a 70-year-old man with type 2 diabetes, acute pancreatitis was diagnosed after 24 weeks of weekly subcutaneous semaglutide 1 mg.
In plain wordsA 70-year-old man with type 2 diabetes developed pancreatitis after 24 weeks on semaglutide. One case does not prove the drug caused it.
Peptide
Semaglutide
Outcome
IncreaseAcute pancreatitis
Study
n = 1
Outcome group
Adverse events · Gastrointestinal
Studied dose
1 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
He was diagnosed with acute pancreatitis and diabetic ketoacidosis (DKA) and admitted to the intensive care unit.
1 context sentence(design, population, supporting numbers)
Summary · context
A 70-year-old male with type 2 diabetes presented to the emergency department with severe abdominal pain and dyspnea after 24 weeks of treatment with weekly subcutaneous semaglutide (1 mg).
Report a problemFND-4239584101
02HumanCase report or seriesSafety outcome
In a 70-year-old man with type 2 diabetes, diabetic ketoacidosis was diagnosed after 24 weeks of weekly subcutaneous semaglutide 1 mg.
In plain wordsA 70-year-old man with type 2 diabetes developed diabetic ketoacidosis after 24 weeks on semaglutide. One case does not prove the drug caused it.
Peptide
Semaglutide
Outcome
IncreaseDiabetic ketoacidosis
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
1 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
He was diagnosed with acute pancreatitis and diabetic ketoacidosis (DKA) and admitted to the intensive care unit.
1 context sentence(design, population, supporting numbers)
Summary · context
A 70-year-old male with type 2 diabetes presented to the emergency department with severe abdominal pain and dyspnea after 24 weeks of treatment with weekly subcutaneous semaglutide (1 mg).
Report a problemFND-4239584102
03HumanCase report or seriesSafety outcome
In a 70-year-old man with type 2 diabetes receiving semaglutide, acute acalculous cholecystitis complicated by gallbladder rupture followed the pancreatitis and ketoacidosis.
In plain wordsA man on semaglutide later developed gallbladder inflammation with rupture. One case does not prove the drug caused it.
Peptide
Semaglutide
Outcome
IncreaseAcute acalculous cholecystitis with gallbladder rupture
Study
n = 1
Outcome group
Adverse events · Gastrointestinal
Studied dose
1 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
A repeat abdominal computed tomography scan revealed acute acalculous cholecystitis complicated by gallbladder rupture.
1 context sentence(design, population, supporting numbers)
Summary · context
A 70-year-old male with type 2 diabetes presented to the emergency department with severe abdominal pain and dyspnea after 24 weeks of treatment with weekly subcutaneous semaglutide (1 mg).
Report a problemFND-4239584103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.